fda approval in cll, recommendation in nsclc, missed endpoint in gbm study, and more
Published 8 years ago • 223 plays • Length 9:46
Download video MP4
Download video MP3
Similar videos
-
11:34
fda approval in cll, recommendation in sts, partial hold on cervical cancer trial, and more
-
7:26
fda approval in ovarian cancer, priority reviews in nsclc, cll, and follicular lymphoma, and more
-
6:27
fda approval in nsclc, and ema regulatory advances in pancreatic cancer, nhl, and cll
-
5:21
fda approvals in cll and all, nda accepted in melanoma, and more
-
8:44
priority review in nsclc, label update in cll, delayed fda decision in lung cancer, and more
-
8:10
fda approval for cll, odac vote in lung cancer, european regulatory advances, and more
-
11:13
fda approval in cll and fl, partial hold lifted in tazmetostat trials, and more
-
13:43
fda approvals in ntrk fusion tumors, ros1 nsclc, and myelofibrosis, and more
-
0:33
onclive news network preview: fda approval in head and neck cancer
-
10:01
fda approvals in sclc and a biosimilar, and japanese approvals in aml, ntrk tumors, and more
-
9:35
fda approvals in breast cancer and of a biosimilar, nda submitted in cll, and more
-
0:31
preview: fda approvals in cll and all, nda accepted in melanoma, and more
-
9:29
fda approvals in all and breast cancer, priority reviews in cml and follicular lymphoma, and more
-
2:07
dr. ferrajoli on the fda approval of ibrutinib in cll
-
9:41
fda approvals in follicular lymphoma and prostate cancer, biosimilar is granted approval, and more
-
8:22
regulatory update: three fda approvals and two priority reviews
-
0:31
preview: fda approval in nsclc and ema regulatory advances
-
11:13
fda approval in her2 early breast cancer, fast track designation in tnbc, and more
-
1:29
dr. byrd on ibrutinib's impact on treatment landscape in cll
Clip.africa.com - Privacy-policy